{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:44:36Z","timestamp":1789469076267,"version":"build-2803163510"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40257-026-01056-9","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:08:12Z","timestamp":1783102092000},"page":"977-995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy"],"prefix":"10.1007","volume":"27","author":[{"given":"Isabel","family":"Heidrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Urhahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-2772","authenticated-orcid":false,"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"5","key":"1056_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158(5):495\u2013503. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0160.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1056_CR2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043. https:\/\/doi.org\/10.3322\/caac.70043.","journal-title":"CA Cancer J Clin"},{"issue":"23","key":"1056_CR3","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMra2034861","volume":"384","author":"BD Curti","year":"2021","unstructured":"Curti BD, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med. 2021;384(23):2229\u201340. https:\/\/doi.org\/10.1056\/NEJMra2034861.","journal-title":"N Engl J Med"},{"issue":"2","key":"1056_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/ddg.12727","volume":"14","author":"C Gebhardt","year":"2016","unstructured":"Gebhardt C, Lichtenberger R, Utikal J. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. J Dtsch Dermatol Ges. 2016;14(2):158\u201364. https:\/\/doi.org\/10.1111\/ddg.12727.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"1056_CR5","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/jdv.16212","volume":"34","author":"S Ertekin","year":"2020","unstructured":"Ertekin S, Podlipnik S, Ribero S, Molina R, Rios J, Carrera C, et al. Monthly changes in serum levels of S100B protein as a predictor of metastasis development in high-risk melanoma patients. J Eur Acad Dermatol Venereol. 2020;34(7):1482\u20138. https:\/\/doi.org\/10.1111\/jdv.16212.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1056_CR6","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/jdv.16731","volume":"34","author":"C Posch","year":"2020","unstructured":"Posch C. A fresh perspective on an established marker: S100B-dynamics for early detection of melanoma recurrence. J Eur Acad Dermatol Venereol. 2020;34(7):1386\u20131386. https:\/\/doi.org\/10.1111\/jdv.16731.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1056_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","volume":"16","author":"K Pantel","year":"2010","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398\u2013406. https:\/\/doi.org\/10.1016\/j.molmed.2010.07.001.","journal-title":"Trends Mol Med"},{"issue":"4","key":"1056_CR8","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858\u201373. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1311.","journal-title":"Cancer Discov"},{"issue":"4","key":"1056_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.tig.2023.01.004","volume":"39","author":"T Moser","year":"2023","unstructured":"Moser T, K\u00fchberger S, Lazzeri I, Vlachos G, Heitzer E. Bridging biological cfDNA features and machine learning approaches. Trends Genet. 2023;39(4):285\u2013307. https:\/\/doi.org\/10.1016\/j.tig.2023.01.004.","journal-title":"Trends Genet"},{"issue":"11","key":"1056_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103978","volume":"9","author":"S Genta","year":"2024","unstructured":"Genta S, Araujo DV, Hueniken K, Pipinikas C, Ventura R, Rojas P, et al. Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open. 2024;9(11):103978. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103978.","journal-title":"ESMO Open"},{"issue":"61","key":"1056_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102519","volume":"6","author":"S Yazaki","year":"2025","unstructured":"Yazaki S, Tokura M, Aiba H, Kojima Y, Shiraishi K. Clinical applications of cell-free DNA-based liquid biopsy analysis. Transl Oncol. 2025;6(61):102519. https:\/\/doi.org\/10.1016\/j.tranon.2025.102519.","journal-title":"Transl Oncol"},{"issue":"2","key":"1056_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00254","volume":"10","author":"VT Ma","year":"2026","unstructured":"Ma VT, Zhou AY, Forati A, Hollnagel F, Patel JD, Burkey C, et al. Multi-institutional study evaluating the role of early circulating tumor DNA dynamics during treatment with immune checkpoint inhibitors in patients with advanced-stage melanoma. JCO Precis Oncol. 2026;10(2):e2500254. https:\/\/doi.org\/10.1200\/PO-25-00254.","journal-title":"JCO Precis Oncol"},{"issue":"38","key":"1056_CR13","doi-asserted-by":"publisher","first-page":"25265","DOI":"10.18632\/oncotarget.25404","volume":"9","author":"G Herbreteau","year":"2018","unstructured":"Herbreteau G, Vall\u00e9e A, Knol AC, Th\u00e9oleyre S, Qu\u00e9reux G, Varey E, et al. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget. 2018;9(38):25265\u201376. https:\/\/doi.org\/10.18632\/oncotarget.25404.","journal-title":"Oncotarget"},{"issue":"22","key":"1056_CR14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1186\/s12967-024-05783-7","volume":"28","author":"S Marchisio","year":"2024","unstructured":"Marchisio S, Ricci AA, Roccuzzo G, Bongiovanni E, Ortolan E, Bertero L, et al. Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment. J Transl Med. 2024;28(22):1074. https:\/\/doi.org\/10.1186\/s12967-024-05783-7.","journal-title":"J Transl Med"},{"issue":"8","key":"1056_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/CJI.0000000000000569","volume":"48","author":"AK Steimle","year":"2025","unstructured":"Steimle AK, Cho SY, Menon N, Jeraj R, Birbrair A, Albertini MR, et al. ctDNA dynamics identifies pseudoprogression in a metastatic melanoma patient treated with nivolumab\/relatlimab. J Immunother. 2025;48(8):325\u20138. https:\/\/doi.org\/10.1097\/CJI.0000000000000569.","journal-title":"J Immunother"},{"issue":"2","key":"1056_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005854","volume":"11","author":"L Al-Showbaki","year":"2023","unstructured":"Al-Showbaki L, Wilson B, Tamimi F, Molto C, Mittal A, Cescon DW, et al. Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11(2):e005854. https:\/\/doi.org\/10.1136\/jitc-2022-005854.","journal-title":"J Immunother Cancer"},{"key":"1056_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102788","volume":"129","author":"E De Simoni","year":"2024","unstructured":"De Simoni E, Spagnolo F, Gandini S, Gaeta A, Rizzetto G, Molinelli E, et al. Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma. Cancer Treat Rev. 2024;129:102788. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102788.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1056_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10555-022-10075-x","volume":"42","author":"I Heidrich","year":"2023","unstructured":"Heidrich I, Deitert B, Werner S, Pantel K. Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. Cancer Metastasis Rev. 2023;42(1):161\u201382. https:\/\/doi.org\/10.1007\/s10555-022-10075-x.","journal-title":"Cancer Metastasis Rev"},{"key":"1056_CR19","doi-asserted-by":"publisher","unstructured":"Gebhardt C, Keller L, Heidrich I, Koett J, Geidel G, Abbott C, et al. Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma. JCO. 2023;41(16_suppl):9562\u20139562. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9562","DOI":"10.1200\/JCO.2023.41.16_suppl.9562"},{"issue":"7974","key":"1056_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41586-023-06333-9","volume":"620","author":"T Nishimura","year":"2023","unstructured":"Nishimura T, Kakiuchi N, Yoshida K, Sakurai T, Kataoka TR, Kondoh E, et al. Evolutionary histories of breast cancer and related clones. Nature. 2023;620(7974):607\u201314. https:\/\/doi.org\/10.1038\/s41586-023-06333-9.","journal-title":"Nature"},{"issue":"10","key":"1056_CR21","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","volume":"41","author":"K Chen","year":"2023","unstructured":"Chen K, Yang F, Shen H, Wang C, Li X, Chervova O, et al. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer. Cancer Cell. 2023;41(10):1749-1762.e6. https:\/\/doi.org\/10.1016\/j.ccell.2023.08.010.","journal-title":"Cancer Cell"},{"issue":"3","key":"1056_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/CMR.0000000000000892","volume":"33","author":"EK Brunsgaard","year":"2023","unstructured":"Brunsgaard EK, Bowles TL, Asare EA, Grossmann K, Boucher KM, Grossmann A, et al. Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma. Melanoma Res. 2023;33(3):184\u201391. https:\/\/doi.org\/10.1097\/CMR.0000000000000892.","journal-title":"Melanoma Res"},{"issue":"17_suppl","key":"1056_CR23","doi-asserted-by":"publisher","first-page":"LBA9515","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9515","volume":"41","author":"MS Carlino","year":"2023","unstructured":"Carlino MS, Khattak A, Weber JS, Meniawy T, Sullivan RJ, Taylor MH, et al. Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157\/V940, a personalized cancer vaccine, and pembrolizumab. JCO. 2023;41(17_suppl):LBA9515\u2013LBA9515. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA9515.","journal-title":"JCO"},{"issue":"6","key":"1056_CR24","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-024-03040-4","volume":"30","author":"AJ Widman","year":"2024","unstructured":"Widman AJ, Shah M, Frydendahl A, Halmos D, Khamnei CC, \u00d8gaard N, et al. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Nat Med. 2024;30(6):1655\u201366. https:\/\/doi.org\/10.1038\/s41591-024-03040-4.","journal-title":"Nat Med"},{"issue":"5","key":"1056_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1373\/clinchem.2017.281543","volume":"64","author":"V Haselmann","year":"2018","unstructured":"Haselmann V, Gebhardt C, Brechtel I, Duda A, Czerwinski C, Sucker A, et al. Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy. Clin Chem. 2018;64(5):830\u201342. https:\/\/doi.org\/10.1373\/clinchem.2017.281543.","journal-title":"Clin Chem"},{"issue":"1","key":"1056_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03457-w","volume":"44","author":"I Heidrich","year":"2025","unstructured":"Heidrich I, Rautmann C, Ly C, Khatri R, K\u00f6tt J, Geidel G, et al. In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition. J Exp Clin Cancer Res. 2025;44(1):202. https:\/\/doi.org\/10.1186\/s13046-025-03457-w.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"1056_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/CMR.0000000000000903","volume":"33","author":"J Kisist\u00f3k","year":"2023","unstructured":"Kisist\u00f3k J, Christensen DS, Rasmussen MH, Duval L, Aggerholm-Pedersen N, Luczak AA, et al. Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel. Melanoma Res. 2023;33(5):364\u201374. https:\/\/doi.org\/10.1097\/CMR.0000000000000903.","journal-title":"Melanoma Res"},{"key":"1056_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1520441","volume":"15","author":"L Liu","year":"2025","unstructured":"Liu L, Hou S, Zhu A, Yan B, Li L, Song D. The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2025;15:1520441. https:\/\/doi.org\/10.3389\/fimmu.2024.1520441.","journal-title":"Front Immunol"},{"issue":"3","key":"1056_CR29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/annonc\/mdy552","volume":"30","author":"C Abbosh","year":"2019","unstructured":"Abbosh C, Swanton C, Birkbak NJ. Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses. Ann Oncol. 2019;30(3):358\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdy552.","journal-title":"Ann Oncol"},{"issue":"3","key":"1056_CR30","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3390\/ijms27031569","volume":"27","author":"N Charbel","year":"2026","unstructured":"Charbel N, Rizkallah J, Bal MN, El Masri A, Armache E, Ghezzawi M, et al. Circulating tumor DNA in melanoma: advances in detection, clinical applications, and integration with emerging technologies. Int J Mol Sci. 2026;27(3):1569. https:\/\/doi.org\/10.3390\/ijms27031569.","journal-title":"Int J Mol Sci"},{"issue":"16_suppl","key":"1056_CR31","doi-asserted-by":"publisher","first-page":"9584","DOI":"10.1200\/JCO.2025.43.16_suppl.9584","volume":"43","author":"VTL Ma","year":"2025","unstructured":"Ma VTL, Hollnagel F, Harris MS, Patel JD, Mannino MC, Schehr JL, et al. Sensitivity of circulating tumor DNA (ctDNA) for disease recurrence or relapse in melanoma patients. J Clin Oncol. 2025;43(16_suppl):9584\u20139584. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9584.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1056_CR32","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1158\/1078-0432.CCR-19-3926","volume":"26","author":"JH Lee","year":"2020","unstructured":"Lee JH, Menzies AM, Carlino MS, McEvoy AC, Sandhu S, Weppler AM, et al. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. Clin Cancer Res. 2020;26(15):4064\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3926.","journal-title":"Clin Cancer Res"},{"key":"1056_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejca.2026.116676","volume":"15","author":"G Geidel","year":"2026","unstructured":"Geidel G, Fekade N, Raabe K, Smit DJ, Adam L, Heidrich I, et al. Translating ctDNA into cutaneous melanoma care: an international expert survey. Eur J Cancer. 2026;15:239. https:\/\/doi.org\/10.1016\/j.ejca.2026.116676.","journal-title":"Eur J Cancer"},{"issue":"16","key":"1056_CR34","doi-asserted-by":"publisher","first-page":"9122","DOI":"10.1038\/s41467-025-64153-z","volume":"14","author":"KT Helzer","year":"2025","unstructured":"Helzer KT, Sharifi MN, Sperger JM, Chrostek MR, Bootsma ML, Reese SR, et al. Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels. Nat Commun. 2025;14(16):9122. https:\/\/doi.org\/10.1038\/s41467-025-64153-z.","journal-title":"Nat Commun"},{"issue":"25","key":"1056_CR35","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1186\/s12885-025-15150-4","volume":"25","author":"J Wang","year":"2025","unstructured":"Wang J, Zhang W, Li H, Wang Y, Qi J, Nie J. Cell-free DNA methylation and fragmentomics-based liquid biopsy for accurate esophageal cancer detection. BMC Cancer. 2025;25(25):1816. https:\/\/doi.org\/10.1186\/s12885-025-15150-4.","journal-title":"BMC Cancer"},{"issue":"9","key":"1056_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023418","volume":"6","author":"F Mouliere","year":"2011","unstructured":"Mouliere F, Robert B, Peyrotte EA, Rio MD, Ychou M, Molina F, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS ONE. 2011;6(9):e23418. https:\/\/doi.org\/10.1371\/journal.pone.0023418.","journal-title":"PLoS ONE"},{"issue":"5","key":"1056_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051188","volume":"13","author":"AB Tigu","year":"2025","unstructured":"Tigu AB, Ivancuta A, Uhl A, Sabo AC, Nistor M, Mure\u0219an XM, et al. Epigenetic therapies in melanoma\u2014targeting DNA methylation and histone modification. Biomedicines. 2025;13(5):1188. https:\/\/doi.org\/10.3390\/biomedicines13051188.","journal-title":"Biomedicines"},{"issue":"2","key":"1056_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jncc.2024.12.007","volume":"5","author":"N Li","year":"2025","unstructured":"Li N, Song K, Chen H, Dai M. Advance and challenge of DNA methylation as cancer biomarkers for risk stratification, screening and early detection. J Natl Cancer Cent. 2025;5(2):108\u201312. https:\/\/doi.org\/10.1016\/j.jncc.2024.12.007.","journal-title":"J Natl Cancer Cent."},{"key":"1056_CR39","doi-asserted-by":"publisher","unstructured":"Ivankovi\u0107 I, Bal\u00e1zs Z, Gitchev T, Trottet C, Moldovan N, Bahce I, et al. The effects of bioinformatics preprocessing on cell-free DNA fragment analysis. Gigascience. 2025;14:giaf139. https:\/\/doi.org\/10.1093\/gigascience\/giaf139.","DOI":"10.1093\/gigascience\/giaf139"},{"issue":"9","key":"1056_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237802","volume":"15","author":"R Woodhouse","year":"2020","unstructured":"Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE. 2020;15(9):e0237802. https:\/\/doi.org\/10.1371\/journal.pone.0237802.","journal-title":"PLoS ONE"},{"issue":"12","key":"1056_CR41","doi-asserted-by":"publisher","first-page":"1662587","DOI":"10.3389\/fmolb.2025.1662587","volume":"15","author":"J Tan","year":"2025","unstructured":"Tan J, Wu Z, Zhu Y, Miao B, Xu D, Gu J, et al. Advances of nanopore direct sequencing technology and bioinformatics analysis for cell-free DNA detection and its clinical applications in cancer liquid biopsy. Front Mol Biosci. 2025;15(12):1662587. https:\/\/doi.org\/10.3389\/fmolb.2025.1662587.","journal-title":"Front Mol Biosci"},{"issue":"16_suppl","key":"1056_CR42","doi-asserted-by":"publisher","first-page":"TPS9603","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9603","volume":"40","author":"R Lee","year":"2022","unstructured":"Lee R, Rothwell DG, Jackson R, Smith N, Wong SQ, Kelso N, et al. DETECTION phase II\/III trial: circulating tumor DNA\u2013guided therapy for stage IIB\/C melanoma after surgical resection. J Clin Oncol. 2022;40(16_suppl):TPS9603\u2013TPS9603. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS9603.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1056_CR43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/annonc\/mdx717","volume":"29","author":"RJ Lee","year":"2018","unstructured":"Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma. Ann Oncol. 2018;29(2):490\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdx717.","journal-title":"Ann Oncol"},{"issue":"5","key":"1056_CR44","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdz048","volume":"30","author":"L Tan","year":"2019","unstructured":"Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019;30(5):804\u201314. https:\/\/doi.org\/10.1093\/annonc\/mdz048.","journal-title":"Ann Oncol"},{"issue":"7","key":"1056_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012034","volume":"13","author":"GV Long","year":"2025","unstructured":"Long GV, Tang H, Desai K, Wang S, Del Vecchio M, Larkin J, et al. Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D\/IV melanoma treated with adjuvant immunotherapy: CheckMate 915. J Immunother Cancer. 2025;13(7):e012034. https:\/\/doi.org\/10.1136\/jitc-2025-012034.","journal-title":"J Immunother Cancer"},{"key":"1056_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/PO.19.00174","volume":"4","author":"J Braune","year":"2020","unstructured":"Braune J, Keller L, Schiller F, Graf E, Rafei-Shamsabadi D, Wehrle J, et al. Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma. JCO Precis Oncol. 2020;4:20\u201331. https:\/\/doi.org\/10.1200\/PO.19.00174.","journal-title":"JCO Precis Oncol"},{"key":"1056_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115141","volume":"214","author":"ILM Reijers","year":"2025","unstructured":"Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, et al. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. Eur J Cancer. 2025;214:115141. https:\/\/doi.org\/10.1016\/j.ejca.2024.115141.","journal-title":"Eur J Cancer"},{"issue":"43","key":"1056_CR48","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13046-024-03153-1","volume":"21","author":"WY Chan","year":"2024","unstructured":"Chan WY, Lee JH, Stewart A, Diefenbach RJ, Gonzalez M, Menzies AM, et al. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy. J Exp Clin Cancer Res. 2024;21(43):238. https:\/\/doi.org\/10.1186\/s13046-024-03153-1.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"1056_CR49","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S1470-2045(25)00139-1","volume":"26","author":"MM Syeda","year":"2025","unstructured":"Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, et al. Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial. Lancet Oncol. 2025;26(5):641\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(25)00139-1.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1056_CR50","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1245\/s10434-025-17194-z","volume":"32","author":"KE Rhodin","year":"2025","unstructured":"Rhodin KE, O\u2019Connor MH, Therien A, Hollander S, Geron V, Nair U, et al. Circulating tumor DNA in high-risk stage ii\/iii cutaneous melanoma: a feasibility study. Ann Surg Oncol. 2025;32(7):5292\u20139. https:\/\/doi.org\/10.1245\/s10434-025-17194-z.","journal-title":"Ann Surg Oncol"},{"key":"1056_CR51","unstructured":"University of Utah. Improving early detection of melanoma recurrence with circulating tumor DNA (ctDNA) [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Mar [cited 2026 Feb 6]. Clinical trial registration no.: NCT05736523. https:\/\/clinicaltrials.gov\/study\/NCT05736523"},{"issue":"1","key":"1056_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","volume":"22","author":"K Pantel","year":"2025","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin Oncol. 2025;22(1):65\u201377. https:\/\/doi.org\/10.1038\/s41571-024-00967-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1056_CR53","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.34716","volume":"129","author":"Z Eroglu","year":"2023","unstructured":"Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, et al. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023;129(11):1723\u201334. https:\/\/doi.org\/10.1002\/cncr.34716.","journal-title":"Cancer"},{"issue":"3","key":"1056_CR54","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/0008-5472.CAN-23-1429","volume":"84","author":"J Heo","year":"2024","unstructured":"Heo J, Kim YN, Shin S, Lee K, Lee JH, Lee YJ, et al. Serial circulating tumor DNA analysis with a tumor-na\u00efve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer. Cancer Res. 2024;84(3):468\u201378. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1429.","journal-title":"Cancer Res"},{"issue":"8","key":"1056_CR55","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1158\/1078-0432.CCR-25-3643","volume":"32","author":"G Ansstas","year":"2026","unstructured":"Ansstas G, Khaddour K, Sudhaman S, Lin K, Budde GL, Poklepovic A, et al. Longitudinal ctDNA monitoring for postsurgical disease surveillance in patients with stage I to IIIB melanoma. Clin Cancer Res. 2026;32(8):1513\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-3643.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1056_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1197","volume":"13","author":"RP Patel","year":"2023","unstructured":"Patel RP, Somasundram PM, Smith LK, Sheppard KE, McArthur GA. The therapeutic potential of targeting minimal residual disease in melanoma. Clin Transl Med. 2023;13(3):e1197. https:\/\/doi.org\/10.1002\/ctm2.1197.","journal-title":"Clin Transl Med"},{"issue":"7","key":"1056_CR57","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","volume":"20","author":"TG Phan","year":"2020","unstructured":"Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20(7):398\u2013411. https:\/\/doi.org\/10.1038\/s41568-020-0263-0.","journal-title":"Nat Rev Cancer"},{"issue":"33","key":"1056_CR58","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 Trial. J Clin Oncol. 2020;38(33):3925\u201336. https:\/\/doi.org\/10.1200\/JCO.20.02110.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1056_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007630","volume":"11","author":"M Haist","year":"2023","unstructured":"Haist M, Stege H, Rogall F, Tan Y, von Wasielewski I, Klespe KC, et al. Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG. J Immunother Cancer. 2023;11(9):e007630. https:\/\/doi.org\/10.1136\/jitc-2023-007630.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1056_CR60","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","volume":"11","author":"EJ Moding","year":"2021","unstructured":"Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021;11(12):2968\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0634.","journal-title":"Cancer Discov"},{"key":"1056_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fonc.2023.1173701","volume":"9","author":"M Bou Zerdan","year":"2023","unstructured":"Bou Zerdan M, Kassab J, Saba L, Haroun E, Bou Zerdan M, Allam S, et al. Liquid biopsies and minimal residual disease in lymphoid malignancies. Front Oncol. 2023;9:13. https:\/\/doi.org\/10.3389\/fonc.2023.1173701.","journal-title":"Front Oncol"},{"issue":"7","key":"1056_CR62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409\u201324. https:\/\/doi.org\/10.1038\/s41571-019-0187-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1056_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcskn.2025.100585","author":"R Lee","year":"2025","unstructured":"Lee R, Rothwell D, Saunders G, Smith N, Bibby SJ, Board R, et al. DETECTION-2 feasibility: a phase 2 trial comparing adjuvant therapy to ctDNA follow-up in resected stage IIB\/IIC\/IIIA melanoma. EJC Skin Cancer. 2025. https:\/\/doi.org\/10.1016\/j.ejcskn.2025.100585.","journal-title":"EJC Skin Cancer"},{"key":"1056_CR64","unstructured":"University of Oxford. A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma With Molecular Relapsed Disease [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Jul [cited 2026 Feb 6]. Clinical trial registration no.: NCT05315258. https:\/\/clinicaltrials.gov\/study\/NCT05315258"},{"key":"1056_CR65","unstructured":"Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection [Internet]. [cited 2026 Feb 6]. https:\/\/clin.larvol.com\/trial-detail\/NCT05060003"},{"key":"1056_CR66","unstructured":"Washington University School of Medicine. A Phase II Randomized Study of Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection [Clinical trial registration] [Internet]. clinicaltrials.gov; 2024 Feb [cited 2026 Feb 23]. Clinical trial registration no.: NCT05060003. https:\/\/clinicaltrials.gov\/study\/NCT05060003"},{"key":"1056_CR67","doi-asserted-by":"publisher","unstructured":"Feng D, Collins L, Callahan MK, Sullivan RJ, Piperno-Neumann S, Nathan PD, et al. Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp. JCO. 2023;41(16_suppl):9589\u20139589. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9589","DOI":"10.1200\/JCO.2023.41.16_suppl.9589"},{"issue":"10","key":"1056_CR68","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/1878-0261.12373","volume":"12","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Luber B, Makell M, Brothers P, Santmyer J, Schollenberger MD, et al. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol. 2018;12(10):1661\u201372. https:\/\/doi.org\/10.1002\/1878-0261.12373.","journal-title":"Mol Oncol"},{"issue":"3","key":"1056_CR69","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41416-021-01507-6","volume":"126","author":"G Marsavela","year":"2022","unstructured":"Marsavela G, McEvoy AC, Pereira MR, Reid AL, Al-Ogaili Z, Warburton L, et al. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. Br J Cancer. 2022;126(3):401\u20138. https:\/\/doi.org\/10.1038\/s41416-021-01507-6.","journal-title":"Br J Cancer"},{"issue":"17","key":"1056_CR70","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12967-019-2051-8","volume":"5","author":"T Seremet","year":"2019","unstructured":"Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;5(17):303. https:\/\/doi.org\/10.1186\/s12967-019-2051-8.","journal-title":"J Transl Med"},{"key":"1056_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113455","volume":"196","author":"A Dayimu","year":"2024","unstructured":"Dayimu A, Gupta A, Matin RN, Nobes J, Board R, Payne M, et al. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM). Eur J Cancer. 2024;196:113455. https:\/\/doi.org\/10.1016\/j.ejca.2023.113455.","journal-title":"Eur J Cancer"},{"key":"1056_CR72","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.2147\/OTT.S248237","volume":"13","author":"A Forschner","year":"2020","unstructured":"Forschner A, Wei\u00dfgraeber S, Hadaschik D, Schulze M, Kopp M, Kelkenberg S, et al. Circulating tumor DNA correlates with outcome in metastatic melanoma treated by BRAF and MEK inhibitors\u2014results of a prospective biomarker study. Onco Targets Ther. 2020;13:5017\u201332. https:\/\/doi.org\/10.2147\/OTT.S248237.","journal-title":"Onco Targets Ther"},{"issue":"10","key":"1056_CR73","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/exd.14901","volume":"32","author":"L Di Nardo","year":"2023","unstructured":"Di Nardo L, Del Regno L, Di Stefani A, Mannino M, Fossati B, Catapano S, et al. The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients. Exp Dermatol. 2023;32(10):1785\u201393. https:\/\/doi.org\/10.1111\/exd.14901.","journal-title":"Exp Dermatol"},{"issue":"5","key":"1056_CR74","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdx026.","journal-title":"Ann Oncol"},{"issue":"12","key":"1056_CR75","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.3390\/cancers12123793","volume":"12","author":"G Marsavela","year":"2020","unstructured":"Marsavela G, Johansson PA, Pereira MR, McEvoy AC, Reid AL, Robinson C, et al. The prognostic impact of circulating tumour DNA in melanoma patients treated with systemic therapies\u2014beyond BRAF mutant detection. Cancers (Basel). 2020;12(12):3793. https:\/\/doi.org\/10.3390\/cancers12123793.","journal-title":"Cancers (Basel)."},{"key":"1056_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100926","author":"Y Malki","year":"2026","unstructured":"Malki Y, Zhou Q, Jiang P, Lo YMD. The comings and goings of cell-free DNA: biological and clinical implications. Med. 2026. https:\/\/doi.org\/10.1016\/j.medj.2025.100926.","journal-title":"Med"},{"issue":"12","key":"1056_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.978996","volume":"17","author":"K Khaddour","year":"2022","unstructured":"Khaddour K, Zhou A, Butt OH, Budde G, Malashevich AK, Ansstas G. Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios. Front Oncol. 2022;17(12):978996. https:\/\/doi.org\/10.3389\/fonc.2022.978996.","journal-title":"Front Oncol"},{"issue":"6","key":"1056_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004226","volume":"10","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Robert C, Brase JC, Gusenleitner D, Gasal E, Garrett J, et al. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J Immunother Cancer. 2022;10(6):e004226. https:\/\/doi.org\/10.1136\/jitc-2021-004226.","journal-title":"J Immunother Cancer"},{"key":"1056_CR79","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00100","volume":"8","author":"A Hernando-Calvo","year":"2024","unstructured":"Hernando-Calvo A, Yang SYC, Vila-Casades\u00fas M, Han M, Liu ZA, Berman AHK, et al. Combined transcriptome and circulating tumor DNA longitudinal biomarker analysis associates with clinical outcomes in advanced solid tumors treated with pembrolizumab. JCO Precis Oncol. 2024;8:e2400100. https:\/\/doi.org\/10.1200\/PO.24.00100.","journal-title":"JCO Precis Oncol"},{"issue":"16","key":"1056_CR80","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","volume":"26","author":"L Basler","year":"2020","unstructured":"Basler L, Gabry\u015b HS, Hogan SA, Pavic M, Bogowicz M, Vuong D, et al. Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition. Clin Cancer Res. 2020;26(16):4414\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0020.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1056_CR81","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","volume":"4","author":"JH Lee","year":"2018","unstructured":"Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 2018;4(5):717\u201321. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5332.","journal-title":"JAMA Oncol"},{"key":"1056_CR82","doi-asserted-by":"publisher","unstructured":"Grossman D, Kim CC, Hartman RI, Berry E, Nelson KC, Okwundu N, et al. Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Melanoma Manag. 2019;6(4):MMT32. https:\/\/doi.org\/10.2217\/mmt-2019-0016","DOI":"10.2217\/mmt-2019-0016"},{"key":"1056_CR83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3262","author":"R Dummer","year":"2026","unstructured":"Dummer R, Deng S, Xie T, Pathan N, Saffari H, Robert C, et al. Exploratory analysis of biomarkers and treatment outcomes from the COLUMBUS study in BRAF V600E\/K-mutant advanced or metastatic melanoma. Clin Cancer Res. 2026. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-3262.","journal-title":"Clin Cancer Res"},{"issue":"158","key":"1056_CR84","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejca.2021.09.019","volume":"30","author":"L Gracie","year":"2021","unstructured":"Gracie L, Pan Y, Atenafu EG, Ward DG, Teng M, Pallan L, et al. Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis. Eur J Cancer. 2021;30(158):191\u2013207. https:\/\/doi.org\/10.1016\/j.ejca.2021.09.019.","journal-title":"Eur J Cancer"},{"key":"1056_CR85","unstructured":"Mooradian M. Pilot Study Evaluation the Use of Serial Plasma Next-generation Sequencing (NGS) as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Nov [cited 2026 Feb 6]. Clinical trial registration no.: NCT06146920. https:\/\/clinicaltrials.gov\/study\/NCT06146920"},{"key":"1056_CR86","unstructured":"Royal Marsden NHS Foundation Trust. Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma [Clinical trial registration] [Internet]. clinicaltrials.gov; 2024 Nov [cited 2026 Feb 6]. Clinical trial registration no.: NCT06710093. https:\/\/clinicaltrials.gov\/study\/NCT06710093"},{"issue":"36","key":"1056_CR87","doi-asserted-by":"publisher","first-page":"S264","DOI":"10.1016\/j.annonc.2025.08.607","volume":"1","author":"RJ Lee","year":"2025","unstructured":"Lee RJ, Mouliere F, Smith N, Tivey A, Board RE, Brayshaw E, et al. 173TiP DyNAMIc trial: Circulating tumour DNA guided adaptive BRAF and MEK inhibitor therapy\u2014a phase II randomised proof of concept study. Ann Oncol. 2025;1(36):S264. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.607.","journal-title":"Ann Oncol"},{"key":"1056_CR88","doi-asserted-by":"publisher","unstructured":"Sanz-Garcia E, Zhao E, Bratman SV, Siu LL. Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges. Sci Adv. 2022;8(4):eabi8618. https:\/\/doi.org\/10.1126\/sciadv.abi8618","DOI":"10.1126\/sciadv.abi8618"},{"issue":"12","key":"1056_CR89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2113535119","volume":"119","author":"AJ Kavran","year":"2022","unstructured":"Kavran AJ, Stuart SA, Hayashi KR, Basken JM, Brandhuber BJ, Ahn NG. Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge. Proc Natl Acad Sci U S A. 2022;119(12):e2113535119. https:\/\/doi.org\/10.1073\/pnas.2113535119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"39","key":"1056_CR90","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008\u201318. https:\/\/doi.org\/10.18632\/oncotarget.5788.","journal-title":"Oncotarget"},{"key":"1056_CR91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fcell.2024.1420360","volume":"2","author":"N Slusher","year":"2024","unstructured":"Slusher N, Jones N, Nonaka T. Liquid biopsy for diagnostic and prognostic evaluation of melanoma. Front Cell Dev Biol. 2024;2:12. https:\/\/doi.org\/10.3389\/fcell.2024.1420360.","journal-title":"Front Cell Dev Biol."},{"issue":"1","key":"1056_CR92","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41698-024-00567-0","volume":"8","author":"MC Scaini","year":"2024","unstructured":"Scaini MC, Catoni C, Poggiana C, Pigozzo J, Piccin L, Leone K, et al. A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance. NPJ Precis Oncol. 2024;8(1):78. https:\/\/doi.org\/10.1038\/s41698-024-00567-0.","journal-title":"NPJ Precis Oncol."},{"key":"1056_CR93","doi-asserted-by":"publisher","unstructured":"Catoni C, Poggiana C, Facchinetti A, Pigozzo J, Piccin L, Chiarion-Sileni V, et al. Investigating the retained inhibitory effect of cobimetinib against p.P124L mutated MEK1: a combined liquid biopsy and in silico approach. Cancers (Basel). 2022;14(17):4153. https:\/\/doi.org\/10.3390\/cancers14174153.","DOI":"10.3390\/cancers14174153"},{"key":"1056_CR94","doi-asserted-by":"publisher","unstructured":"Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, et al. Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial. Cell Rep Med. 2024;5(3):101435. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101435.","DOI":"10.1016\/j.xcrm.2024.101435"},{"key":"1056_CR95","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.2147\/OTT.S117121","volume":"10","author":"E Mu\u00f1oz-Couselo","year":"2017","unstructured":"Mu\u00f1oz-Couselo E, Adelantado EZ, Ortiz C, Garc\u00eda JS, Perez-Garcia J. NRAS-mutant melanoma: current challenges and future prospect. Onco Targets Ther. 2017;10:3941\u20137. https:\/\/doi.org\/10.2147\/OTT.S117121.","journal-title":"Onco Targets Ther"},{"key":"1056_CR96","unstructured":"Mooradian M. Pilot Study Evaluation the Use of Serial Plasma Next-generation Sequencing (NGS) as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Nov [cited 2026 Feb 23]. Clinical trial registration no.: NCT06146920. https:\/\/clinicaltrials.gov\/study\/NCT06146920"},{"issue":"1","key":"1056_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03398-4","volume":"44","author":"K Pantel","year":"2024","unstructured":"Pantel K, Alix-Panabi\u00e8res C, Hofman P, Stoecklein NH, Lu YJ, Lianidou E, et al. Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS). J Exp Clin Cancer Res. 2024;44(1):156. https:\/\/doi.org\/10.1186\/s13046-025-03398-4.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"1056_CR98","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/s44321-024-00082-6","volume":"16","author":"M Sementsov","year":"2024","unstructured":"Sementsov M, Ott L, K\u00f6tt J, Sartori A, Lusque A, Degenhardt S, et al. Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma. EMBO Mol Med. 2024;16(7):1560\u201378. https:\/\/doi.org\/10.1038\/s44321-024-00082-6.","journal-title":"EMBO Mol Med"},{"issue":"12","key":"1056_CR99","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/s43018-021-00272-y","volume":"2","author":"S Garc\u00eda-Silva","year":"2021","unstructured":"Garc\u00eda-Silva S, Benito-Mart\u00edn A, Nogu\u00e9s L, Hern\u00e1ndez-Barranco A, Mazariegos MS, Santos V, et al. Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. Nat Cancer. 2021;2(12):1387\u2013405. https:\/\/doi.org\/10.1038\/s43018-021-00272-y.","journal-title":"Nat Cancer."},{"issue":"1","key":"1056_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53908-9","volume":"15","author":"A Forsthuber","year":"2024","unstructured":"Forsthuber A, Aschenbrenner B, Korosec A, Jacob T, Annusver K, Krajic N, et al. Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy. Nat Commun. 2024;15(1):9678. https:\/\/doi.org\/10.1038\/s41467-024-53908-9.","journal-title":"Nat Commun"},{"issue":"4","key":"1056_CR101","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","volume":"22","author":"S Kalaora","year":"2022","unstructured":"Kalaora S, Nagler A, Wargo JA, Samuels Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022;22(4):195\u2013207. https:\/\/doi.org\/10.1038\/s41568-022-00442-9.","journal-title":"Nat Rev Cancer"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01056-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01056-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01056-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:32:07Z","timestamp":1789464727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01056-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01056-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.H. has received honoraria for a scientific presentation from Sysmex Inostics. GG received honoraria from Almirall Hermal GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, and Janssen-Cilag GmbH for lectures and presentations. C.G. is a board member of the Hiege Stiftung \u2013 Die Deutsche Hautkrebsstiftung, unpaid. C.G. has research support from BMS, Novartis, Pierre-Fabre, Regeneron, and Sanofi. C.G. is a member of the advisory board of BioNTech, BMS, Immunocore, MSD, Novartis, Pierre-Fabre, Regeneron, Sanofi, SUN Pharma, and Sysmex. C.G. has received honoraria from BMS, GSK, Immunocore, MSD, Novartis, Pierre Fabre, Regeneron, Sanofi, Sun Pharma, and Sysmex. K.P. has received funding from the EU\/IHI (GUIDE.MRD) and speaker honoraria from MSD. S.U. and D.J.S. have no conflict of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.H., S.U., D.J.S. and K.P. reviewed the literature and wrote the original draft of the manuscript. I.H., S.U., C.G., D.J.S. and K.P. commented on and critically revised the original draft. All authors have read and agreed to the final version of the manuscript.","order":3,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}